Literature DB >> 7472845

Bone mineral density during treatment of central precocious puberty.

E K Neely1, L K Bachrach, R L Hintz, R L Habiby, C W Slemenda, L Feezle, O H Pescovitz.   

Abstract

Treatment of adults with gonadotropin releasing hormone analogs has resulted in rapid loss in bone mineral density (BMD). We measured lumbar and femoral neck BMD by dual-energy x-ray absorptiometry during 2 years of depot leuprolide therapy in 13 girls (mean age, 7.5 years; mean bone age, 10.9 years). At baseline, BMD was elevated for age and concordant with the advanced skeletal age. During therapy with gonadotropin releasing hormone analog, BMD values increased and BMD standard deviation scores for age and skeletal age did not change.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472845     DOI: 10.1016/s0022-3476(95)70182-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.

Authors:  Simone Kapteijns-van Kordelaar; Kees Noordam; Barto Otten; Joop van den Bergh
Journal:  Eur J Pediatr       Date:  2003-09-17       Impact factor: 3.183

2.  Fractures in spina bifida from childhood to young adulthood.

Authors:  A Trinh; P Wong; J Brown; S Hennel; P R Ebeling; P J Fuller; F Milat
Journal:  Osteoporos Int       Date:  2016-08-24       Impact factor: 4.507

Review 3.  Transgender medicine - puberty suppression.

Authors:  Leonidas Panagiotakopoulos
Journal:  Rev Endocr Metab Disord       Date:  2018-09       Impact factor: 6.514

Review 4.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

5.  Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.

Authors:  S Bertelloni; G I Baroncelli; M C Sorrentino; G Perri; G Saggese
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

6.  An Examination of the Effects of Leuprolide Acetate Used in the Treatment of Central Precocious Puberty on Bone Mineral Density and 25-Hydroxy Vitamin D.

Authors:  A Kaya; A Cayir; M I Turan; B Ozkan
Journal:  West Indian Med J       Date:  2015-01-21       Impact factor: 0.171

Review 7.  Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies.

Authors:  Zhongbo Liu; Subburaman Mohan; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2015-12-31       Impact factor: 2.372

8.  Effect of testosterone on bone mineral gain: observations of male patients with growth hormone deficiency and normal gonadotropin secretion.

Authors:  Sanae Kanazawa; Megumi Kojima; Satomi Koyama; Osamu Arisaka
Journal:  Clin Pediatr Endocrinol       Date:  2004-07-07

9.  Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?

Authors:  Doğuş Vurallı; Ayfer Alikaşifoğlu; İrem İyigün; Dicle Canoruç; Alev Ozon; Nazlı Gönç; Nurgün Kandemir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-07-26

Review 10.  Pros and cons of GnRHa treatment for early puberty in girls.

Authors:  Ruben H Willemsen; Daniela Elleri; Rachel M Williams; Ken K Ong; David B Dunger
Journal:  Nat Rev Endocrinol       Date:  2014-04-08       Impact factor: 43.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.